FI941199A0 - Immunoreaktiva polypeptidkompositioner av hepatit C virus - Google Patents

Immunoreaktiva polypeptidkompositioner av hepatit C virus

Info

Publication number
FI941199A0
FI941199A0 FI941199A FI941199A FI941199A0 FI 941199 A0 FI941199 A0 FI 941199A0 FI 941199 A FI941199 A FI 941199A FI 941199 A FI941199 A FI 941199A FI 941199 A0 FI941199 A0 FI 941199A0
Authority
FI
Finland
Prior art keywords
immunoreactive
hepatitis
polypeptide compositions
virus polypeptide
compositions
Prior art date
Application number
FI941199A
Other languages
English (en)
Finnish (fi)
Other versions
FI112438B (sv
FI941199A (sv
Inventor
Amy J Weiner
Michael Houghton
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25056174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI941199(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of FI941199A0 publication Critical patent/FI941199A0/sv
Publication of FI941199A publication Critical patent/FI941199A/sv
Application granted granted Critical
Publication of FI112438B publication Critical patent/FI112438B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/82—Hepatitis associated antigens and antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI941199A 1991-09-13 1994-03-14 DNA-molekyl och förfarande för detektering av antikroppar mot hepatit typ C virus FI112438B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75957591A 1991-09-13 1991-09-13
US75957591 1991-09-13
US9207683 1992-09-11
PCT/US1992/007683 WO1993006126A1 (en) 1991-09-13 1992-09-11 Immunoreactive hepatitis c virus polypeptide compositions

Publications (3)

Publication Number Publication Date
FI941199A0 true FI941199A0 (sv) 1994-03-14
FI941199A FI941199A (sv) 1994-04-27
FI112438B FI112438B (sv) 2003-12-15

Family

ID=25056174

Family Applications (1)

Application Number Title Priority Date Filing Date
FI941199A FI112438B (sv) 1991-09-13 1994-03-14 DNA-molekyl och förfarande för detektering av antikroppar mot hepatit typ C virus

Country Status (16)

Country Link
US (6) US5756312A (sv)
EP (1) EP0608261B1 (sv)
JP (5) JPH06511149A (sv)
AT (1) ATE228564T1 (sv)
AU (1) AU679429B2 (sv)
BG (1) BG62973B1 (sv)
CA (1) CA2116764C (sv)
DE (1) DE69232859T2 (sv)
DK (1) DK0608261T3 (sv)
ES (1) ES2182822T3 (sv)
FI (1) FI112438B (sv)
HU (1) HU227510B1 (sv)
PL (2) PL171972B1 (sv)
RO (1) RO116199B1 (sv)
RU (2) RU2136311C1 (sv)
WO (1) WO1993006126A1 (sv)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596476B1 (en) * 1989-12-22 2003-07-22 Abbott Laboratories Hepatitis C assay
DE69232859T2 (de) * 1991-09-13 2003-04-10 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden
US6297048B1 (en) * 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
US6667387B1 (en) 1996-09-30 2003-12-23 N.V. Innogenetics S.A. HCV core peptides
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
EP0671926B1 (en) * 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
US7255997B1 (en) 1993-04-27 2007-08-14 N.V. Innogenetics S.A. Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
CA2139100C (en) 1993-04-27 2009-06-23 Geert Maertens New sequences of hepatitis c virus genotypes and their use as therapeutic and diagnostic agents
CA2162557C (en) 1993-05-12 2004-09-28 Amy J. Weiner Conserved motif of hepatitis c virus e2/ns1 region
US5514539A (en) * 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
EP0992580B1 (en) 1993-11-04 2005-03-09 Innogenetics N.V. Immunodominant human T-cell epitopes of Hepatitis C virus
ATE331952T1 (de) 1994-07-25 2006-07-15 Roche Diagnostics Gmbh Bestimmung von spezifischem immunglobulin unter verwendung multipler antigene
DE69526636D1 (de) * 1994-07-29 2002-06-13 Innogenetics Nv Gereinigte hepatitis-c-virus hüllproteine zur diagnostischen und therapeutischen verwendung
EP1076092A3 (en) * 1994-10-21 2001-03-28 Innogenetics N.V. Sequences of hepatitis C virus type10 and their use as prophylactic, therapeutic and diagnostic agents
US6110465A (en) * 1995-06-07 2000-08-29 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of hypervariable region 1 of the envelope 2 gene of isolates of hepatitis C virus and the use of reagents derived from these hypervariable sequences in diagnostic methods and vaccines
US7235394B1 (en) 1995-08-29 2007-06-26 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US6127116A (en) * 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US7045363B2 (en) * 1996-05-01 2006-05-16 Fujirebio Inc. Nucleic acid-bound polypeptide method of producing nucleic acid-bound polypeptide and immunoassay using the polypeptide
US6001613A (en) * 1996-05-24 1999-12-14 Board Of Regents Of University Of Nebraska Plasmid bearing a cDNA copy of the genome of bovine viral diarrhea virus, chimeric derivatives thereof, and method of producing an infectious bovine viral diarrhea virus using said plasmid
ATE423204T1 (de) 1996-11-08 2009-03-15 Us Gov Health & Human Serv Herstellung und reinigung von hepatitis c virus- ähnlichen partikeln
US6322965B1 (en) * 1997-02-10 2001-11-27 Advanced Life Science Institute, Inc. Chimera antigen peptide
US7049428B1 (en) * 1998-03-04 2006-05-23 Washington University HCV variants
US7338759B1 (en) 1997-03-04 2008-03-04 Washington University HCV variants
ATE482974T1 (de) * 1997-11-06 2010-10-15 Innogenetics Nv Multimere peptide, die auf dem hepatitis c virus hüllprotein basieren, für diagnostische verwendung und für impfzwecke
US7157435B2 (en) 1998-04-15 2007-01-02 The Regents Of The University Of California Methods for modulation of the effects of aging on the primate brain
US6451306B1 (en) 1998-04-15 2002-09-17 The Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
US6815431B2 (en) 1998-04-15 2004-11-09 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
US6683058B1 (en) 1998-04-15 2004-01-27 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
US7052830B1 (en) * 1998-06-09 2006-05-30 Branch Andrea D Hepatitis C virus peptides and uses thereof
US7108855B2 (en) * 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US6548634B1 (en) * 1998-09-30 2003-04-15 Chiron Corporation Synthetic peptides having FGF receptor affinity
US20030180284A1 (en) * 1998-11-05 2003-09-25 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
US7091324B2 (en) 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
CA2360347C (en) * 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
ES2299276T3 (es) 1998-12-31 2008-05-16 Novartis Vaccines And Diagnostics, Inc. Polipeptidos env del vih modificados.
JP2003523721A (ja) * 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
US6740323B1 (en) 1999-11-24 2004-05-25 Chiron Corporation HBV/HCV virus-like particle
EP1535628B1 (en) * 1999-11-24 2013-07-31 Novartis Vaccines and Diagnostics, Inc. Hbv/hcv virus-like particle
AU6175801A (en) * 2000-07-19 2002-02-05 Univ California Methods for therapy of neurodegenerative disease of the brain
US6858590B2 (en) * 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6680059B2 (en) * 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) * 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
AU9215101A (en) 2000-08-17 2002-02-25 Tripep Ab Vaccines containing ribavirin and methods of use thereof
AU2001292667A1 (en) 2000-09-13 2002-03-26 Hawaii Biotechnology Group, Inc. Immunogenic composition of hepatitis c and methods of use thereof
EP2280074A3 (en) 2001-07-05 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
EP1427806A4 (en) * 2001-08-31 2006-04-26 Chiron Corp ANTIGENIC HIV-TYPE B POLYPEPTIDE-CODING POLYNUCLEOTIDES, POLYPEPTIDES, AND USES THEREOF
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US20070073048A1 (en) 2003-05-15 2007-03-29 Ying Lian Hiv polynucleotides and polypeptides derived from botswana mj4
WO2005010035A2 (en) * 2003-07-22 2005-02-03 Branch Andrea D Alternate reading frame polypeptides derived from hepatitis c and methods of their use
WO2005017125A2 (en) * 2003-08-14 2005-02-24 California Institute Of Molecular Medicine Method for isolation and replication of infectious human hepatitis-c virus
US8124747B2 (en) 2003-08-29 2012-02-28 Innogenetics HCV clade and prototype sequences thereof
EP1814583A2 (en) 2004-11-01 2007-08-08 Novartis Vaccines and Diagnostics, Inc. Combination approaches for generating immune responses
US7968697B2 (en) * 2005-05-25 2011-06-28 Chrontech Pharma Ab Hepatitis C virus non-structural NS3/4A fusion gene
CA2637600A1 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
EP2185195A2 (en) * 2007-08-16 2010-05-19 Tripep Ab Immunogen platform
US20090214593A1 (en) * 2007-08-16 2009-08-27 Tripep Ab Immunogen platform
US20100286070A1 (en) * 2007-09-14 2010-11-11 Gert Verheyden Affinity tag
BRPI0816837B1 (pt) 2007-09-28 2022-10-18 Portola Pharmaceuticals, Inc Composições farmacêuticas, polipeptídeo isolado de duas cadeias e uso de uma composição farmacêutica
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
ES2607935T3 (es) 2009-03-30 2017-04-04 Portola Pharmaceuticals, Inc. Antídotos para inhibidores del factor Xa y procedimientos de uso de los mismos
WO2010148117A1 (en) 2009-06-17 2010-12-23 Scantibodies Laboratory, Inc. Therapeutic and diagnostic affinity purified specific polyclonal antibodies
CA2767858C (en) 2009-07-15 2019-02-12 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same
US9636410B2 (en) 2011-07-06 2017-05-02 Glaxosmithkline Biologicals Sa Cationic oil-in-water emulsions
US9655845B2 (en) 2011-07-06 2017-05-23 Glaxosmithkline Biologicals, S.A. Oil-in-water emulsions that contain nucleic acids
WO2013016449A2 (en) 2011-07-26 2013-01-31 Indicator Systems International, Inc. Assays for the detection of microbes
FR2984328B1 (fr) 2011-12-20 2016-12-30 Bio-Rad Innovations Procede de detection d'une infection par le virus de l'hepatite c
CN104394880B (zh) 2012-03-16 2020-08-28 大学保健网络 用于调节toso活性的方法和组合物
RU2520710C1 (ru) * 2012-12-10 2014-06-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Челябинская государственная медицинская академия" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО ЧелГМА Минздравсоцразвития России) Способ прогнозирования персистенции онкогенных типов вируса папилломы человека в цервикальном эпителии
AU2015225867B2 (en) 2014-03-07 2020-02-06 University Health Network Methods and compositions for modifying the immune response
RU2675108C2 (ru) * 2015-06-15 2018-12-17 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт биомедицинской химии имени В.Н. Ореховича" (ИБМХ) Композиция на основе синтетических пептидов и липидов для вакцины против гепатита с
US10287338B2 (en) 2015-07-10 2019-05-14 Miran NERSISSIAN Factor VIII protein compositions and methods of treating of hemophilia A
EP3365027B1 (en) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Hu specific antibodies and their use in inhibiting biofilm
WO2018129078A1 (en) 2017-01-04 2018-07-12 Research Institute At Nationwide Children's Hospital Dnabii vaccines and antibodies with enhanced activity
US12098188B2 (en) 2017-01-04 2024-09-24 Research Institute At Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
CA3056088A1 (en) 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
CN114401986A (zh) 2019-07-08 2022-04-26 国家儿童医院研究所 破坏生物膜的抗体组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3400079A1 (de) * 1984-01-03 1985-07-11 Röhm GmbH, 6100 Darmstadt Wasserspreitendes kunststoffmaterial, verfahren zu seiner herstellung u. verwendung als verglasungs- und bedachungsmaterial
NZ219516A (en) * 1987-02-10 1991-02-26 Wellcome Found Fusion proteins of hbcag (hepatitis b virus core antigen)
HU216017B (hu) * 1987-11-18 1999-04-28 Chiron Corp. Eljárás HCV-1 polipeptidek, HCV-1 polinukleotidok, rekombináns vektorok és gazdasejtek, valamint immunesszé kit, hepatitis C vírusfertőzés elleni vakcinák, a fertőzés kimutatására szolgáló diagnosztikumok előállítására, és immunvizsgálati és vírustenyészt
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
HU225068B1 (en) * 1989-03-17 2006-05-29 Chiron Corp Process for producing diagnostics and vaccine of nanbh
RO113059B1 (ro) * 1989-05-18 1998-03-30 Chiron Corp Polinucleotida capabila de hibridizare pe o secventa hcv, metoda pentru detectarea unei secvente hcv si procedeu de eliminare a hcv din sange
CA2065287C (en) * 1989-09-15 1999-12-21 Tatsuo Miyamura New hcv isolates
US5372928A (en) * 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
DK0770679T4 (da) * 1990-11-03 2010-05-10 Siemens Healthcare Diagnostics HCV-specifikke peptider, sammensætninger dertil og anvendelse deraf
DE69232859T2 (de) * 1991-09-13 2003-04-10 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden

Also Published As

Publication number Publication date
RU2136311C1 (ru) 1999-09-10
CA2116764C (en) 1999-12-07
CA2116764A1 (en) 1993-04-01
FI112438B (sv) 2003-12-15
BG98653A (bg) 1995-05-31
US5728520A (en) 1998-03-17
RO116199B1 (ro) 2000-11-30
JP4353905B2 (ja) 2009-10-28
RU2212899C2 (ru) 2003-09-27
BG62973B1 (bg) 2000-12-29
US5756312A (en) 1998-05-26
EP0608261A4 (en) 1995-03-15
HU227510B1 (en) 2011-07-28
US6303292B1 (en) 2001-10-16
US5670153A (en) 1997-09-23
WO1993006126A1 (en) 1993-04-01
DE69232859D1 (de) 2003-01-16
JP2008133301A (ja) 2008-06-12
PL171972B1 (pl) 1997-07-31
ATE228564T1 (de) 2002-12-15
JP2004073207A (ja) 2004-03-11
PL171489B1 (pl) 1997-05-30
EP0608261B1 (en) 2002-11-27
JPH06511149A (ja) 1994-12-15
HUT67342A (en) 1995-03-28
FI941199A (sv) 1994-04-27
HU9400741D0 (en) 1994-06-28
JP2005176853A (ja) 2005-07-07
EP0608261A1 (en) 1994-08-03
JP2002167336A (ja) 2002-06-11
ES2182822T3 (es) 2003-03-16
AU679429B2 (en) 1997-07-03
DE69232859T2 (de) 2003-04-10
US5766845A (en) 1998-06-16
AU2643692A (en) 1993-04-27
US5670152A (en) 1997-09-23
DK0608261T3 (da) 2003-03-17

Similar Documents

Publication Publication Date Title
FI941199A0 (sv) Immunoreaktiva polypeptidkompositioner av hepatit C virus
FI935808A0 (fi) Hepatit-C-virus (HCV) polypeptider
RU94024561A (ru) Иммунореактивные композиции, способ получения композиции, способы получения и обнаружения антител, набор днк, клетка-хозяин, способ получения белка
DK643387A (da) T-celle-epitoper af hepatitis b-virus-nucleocapsid-protein
ATA117890A (de) Komplexes virales antigen von hiv-1 bindendes rekombinantes protein
FI932561A0 (fi) Proteiner med foeraendrade epitoper och foerfaranden foer deras framstaellning
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
DE69433971D1 (de) Von menschlichen T-Zellen immunodominante Epitopen des Virus der C-Hepatitis
NZ512056A (en) HBV core antigen particles with multiple immunogenic components attached via peptide ligands
ATA257190A (de) Virales polypeptid
DE69232906T2 (de) Detektion des Hepatis-C Virus.
DK0935609T3 (da) Krystalliserbare præparater omfattende et hepatitis-C-virus-NS3-proteasedomæne/NS4A-kompleks og dermed opnåede krystaller
DK139083D0 (da) Sma peptider med specificiteten af mund- og klovesyge virale antigener
DK88988D0 (da) T- og b-celleepitoper af pre-s-regionen af hepatitis-b-virus-overfladeantigen
ITRM920350A0 (it) Epitopi immunologicamente omologhi di hla e proteine del virus hiv.
ATE382696T1 (de) Immunoreaktive antigene des hepatitis e viruses
AU2370592A (en) Epitopes of the env protein of the hepatitis c virus
DE69928064D1 (de) Mimotopen der hypervariabele region des e2 glykoproteins von hcv und deren verwendungen
DE3751834D1 (de) Selbstantigen der primären lebercirrhose
DK196689A (da) Ekspression af praes2-proteinet for hepatitis b i methylotrophe gaerarter
JPS5692219A (en) Purification of biologically original particle* particularly antigen *aghbs* of b type hepatitis virus surface
NO20001397D0 (no) Hepatitt B-virus-polypeptider
AU7909391A (en) Epitopes of the pre-s region of hepatitis b virus surface antigen
RU93043621A (ru) Способы получения гликопротеинов нсv, способ очистки, аналитический набор, способ выявления нсv, способ элиминации нсv, способ индукции иммунитета, гликопротеины, иммунореагенты
FI940524A0 (sv) Peptider och polypeptider av västlig subtyp av FSME-virus samt kompositioner och diagnostiska medel innehållande dem

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Free format text: NOVARTIS VACCINES AND DIAGNOSTICS, INC.

MA Patent expired